High expression of PIG11 correlates with poor prognosis in gastric cancer

Gu,Juan; Zhang,Shu; He,Xin; Chen,Sufang; Wang,Yan

doi:10.3892/etm.2021.9680

High expression of PIG11 correlates with poor prognosis in gastric cancer

Authors:
- Juan Gu
- Shu Zhang
- Xin He
- Sufang Chen
- Yan Wang
View Affiliations

Affiliations: Department of Public Health, Jiangsu Vocational College of Medicine, Yancheng, Jiangsu 224005, P.R. China, Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Medical Imaging and Laboratory, Xiangnan University, Chenzhou, Hunan 423000, P.R. China
Published online on: January 22, 2021 https://doi.org/10.3892/etm.2021.9680
Article Number: 249
Copyright: © Gu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

P53‑induced gene 11 (PIG11) is an early transcription‑related target of p53 that is involved in cell apoptosis and tumor development. However, its biological function in gastric cancer (GC) tissues and relationship with the prognosis of patients with GC have remained elusive. In the present retrospective study, 60 fresh and 790 paraffin‑embedded samples of GC were obtained from the Affiliated Hospital of Nantong University (Nantong, China) with complete clinical data from all patients. Reverse transcription‑quantitative PCR and tissue microarray‑immunohistochemical analysis were used to determine the expression of PIG11 in the respective GC tissues. A receiver operating characteristic (ROC) curve was plotted to determine the diagnostic utility of PIG11 expression in GC. Furthermore, three online databases, including Gene Expression Profiling Interactive Analysis (GEPIA), Oncomine and Kaplan‑Meier plotter, were used for bioinformatics analysis of PIG11. PIG11 expression in GC tissues was high, which was positively correlated with invasive depth (P<0.001), lymph node metastasis (P<0.001), distant metastasis (P=0.019), TNM staging (P<0.001) and carcinoembryonic antigen in serum (P<0.001), and negatively associated with the overall survival of patients with GC. The ROC curve analysis suggested that based on PIG11 expression, it was possible to distinguish GC tissues from adjacent normal tissues (P<0.0001) with a sensitivity and specificity of 81.67 and 76.67%, respectively. In addition, Cox logistic regression analysis demonstrated that high PIG11 expression is a novel biomarker for unfavorable prognosis of patients with GC. Furthermore, the results obtained from the GEPIA database indicated that PIG11 expression is correlated with TNF, carcinoembryonic antigen related cell adhesion molecule 5, phosphatidylinositol‑4, 5‑bisphosphate 3‑kinase catalytic subunit alpha, VEGFA and kinase insert domain receptor. Therefore, PIG11 expression may be associated with the malignancy of GC and may serve as a potential diagnostic and prognostic biomarker for GC.

View Figures

View References

1	Li Y, Xu Q, Yang W, Wu T and Lu X: Oleanolic acid reduces aerobic glycolysis-associated proliferation by inhibiting yes-associated protein in gastric cancer cells. Gene. 712(143956)2019.PubMed/NCBI View Article : Google Scholar
2	Cavatorta O, Scida S, Miraglia C, Barchi A, Nouvenne A, Leandro G, Meschi T, De' Angelis GL and Di Mario F: Epidemiology of gastric cancer and risk factors. Acta Biomed. 89:82–87. 2018.PubMed/NCBI View Article : Google Scholar
3	Laterza L, Scaldaferri F and Gasbarrini A: Risk factors for gastric cancer: Is it time to discard PPIs? Gut. 68:176–177. 2019.PubMed/NCBI View Article : Google Scholar
4	Venerito M, Vasapolli R, Rokkas T and Malfertheiner P: Gastric cancer: Epidemiology, prevention, and therapy. Helicobacter. 23 (Suppl 1)(e12518)2018.PubMed/NCBI View Article : Google Scholar
5	Rawla P and Barsouk A: Epidemiology of gastric cancer: Global trends, risk factors and prevention. Prz Gastroenterol. 14:26–38. 2019.PubMed/NCBI View Article : Google Scholar
6	Zang YS, Dai C, Xu X, Cai X, Wang G, Wei J, Wu A, Sun W, Jiao S and Xu Q: Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. Cancer Med. 8:4699–4708. 2019.PubMed/NCBI View Article : Google Scholar
7	Arimoto T, Katagiri T, Oda K, Tsunoda T, Yasugi T, Osuga Y, Yoshikawa H, Nishii O, Yano T and Nakamura Y: Genome-wide cDNA microarray analysis of gene-expression profiles involved in ovarian endometriosis. Int J Oncol. 22:551–560. 2003.PubMed/NCBI
8	Ricketts SL, Carter JC and Coleman WB: Identification of three 11p11.2 candidate liver tumor suppressors through analysis of known human genes. Mol Carcinog. 36:90–99. 2003.PubMed/NCBI View Article : Google Scholar
9	Polyak K, Xia Y, Zweier J, Kinzler K and Vogelstein B: A model for p53-induced apoptosis. Nature. 389:300–305. 1997.PubMed/NCBI View Article : Google Scholar
10	Liang XQ, Cao EH, Zhang Y and Qin JF: A P53 target gene, PIG11, contributes to chemosensitivity of cells to arsenic trioxide. FEBS Lett. 569:94–98. 2004.PubMed/NCBI View Article : Google Scholar
11	Liang XQ, Cao EH, Zhang Y and Qin JF: P53-induced gene 11 (PIG11) involved in arsenic trioxide-induced apoptosis in human gastric cancer MGC-803 cells. Oncol Rep. 10:1265–1269. 2003.PubMed/NCBI
12	Xu L, Hui A, Albanis E, Arthur M, O'Byrne S, Blaner W, Mukherjee P, Friedman S and Eng F: Human hepatic stellate cell lines, LX-1 and LX-2: New tools for analysis of hepatic fibrosis. Gut. 54:142–151. 2005.PubMed/NCBI View Article : Google Scholar
13	Liu XM, Xiong XF, Song Y, Tang RJ, Liang XQ and Cao EH: Possible roles of a tumor suppressor gene PIG11 in hepatocarcinogenesis and As₂O₃-induced apoptosis in liver cancer cells. J Gastroenterol. 44:460–469. 2009.PubMed/NCBI View Article : Google Scholar
14	Wang Y, Liu X, Liu G, Wang X, Hu R and Liang X: PIG11 over-expression predicts good prognosis and induces HepG2 cell apoptosis via reactive oxygen species-dependent mitochondrial pathway. Biomed Pharmacother. 108:435–442. 2018.PubMed/NCBI View Article : Google Scholar
15	Zhu B, Tian T and Zhao M: MiR-645 promotes proliferation and migration of non-small cell lung cancer cells by targeting TP53I11. Eur Rev Med Pharmacol Sci. 24:6150–6156. 2020.PubMed/NCBI View Article : Google Scholar
16	Xiao T, Xu Z, Zhang H, Geng J, Qiao Y, Liang Y, Yu Y, Dong Q and Suo G: TP53I11 suppresses epithelial-mesenchymal transition and metastasis of breast cancer cells. BMB Rep. 52:379–384. 2019.PubMed/NCBI View Article : Google Scholar
17	Li Z and Li Q: The latest 2010 WHO classification of tumors of digestive system. Zhonghua Bing Li Xue Za Zhi. 40:351–354. 2011.PubMed/NCBI(In Chinese).
18	He X, Wu W, Lin Z, Ding Y, Si J and Sun L: Validation of the American Joint Committee on Cancer (AJCC) 8th edition stage system for gastric cancer patients: A population-based analysis. Gastric Cancer. 21:391–400. 2018.PubMed/NCBI View Article : Google Scholar
19	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017.PubMed/NCBI View Article : Google Scholar
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
21	Wang Y, Chen S, Tian W, Zhang Q, Jiang C, Qian L and Liu Y: High-expression HBO1 predicts poor prognosis in gastric cancer. Am J Clin Pathol. 152:517–526. 2019.PubMed/NCBI View Article : Google Scholar
22	Camp R, Dolled-Filhart M and Rimm D: X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 10:7252–7259. 2004.PubMed/NCBI View Article : Google Scholar
23	Szasz AM, Lanczky A, Nagy A, Forster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabo A and Gyorffy B: Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 7:49322–49333. 2016.PubMed/NCBI View Article : Google Scholar
24	Röcken C: Molecular classification of gastric cancer. Expert Rev Mol Diagn. 17:293–301. 2017.PubMed/NCBI View Article : Google Scholar
25	Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, Kim SM, Kim SB, Kim H, Hong SW, Park YN, et al: Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res. 17:1850–1857. 2011.PubMed/NCBI View Article : Google Scholar
26	Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, et al: Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 5(e1000676)2009.PubMed/NCBI View Article : Google Scholar
27	Guo S, Shang M, Dong Z, Zhang J, Wang Y and Zhao Y: The assessment of the optimal number of examined lymph nodes and prognostic models based on lymph nodes for predicting survival outcome in patients with stage N3b gastric cancer. Asia Pac J Clin Oncol: Aug 6, 2020 doi: 10.1111/ajco.13358 (Epub ahead of print).
28	Tan AC, Chan DL, Faisal W and Pavlakis N: New drug developments in metastatic gastric cancer. Therap Adv Gastroenterol. 11(1756284818808072)2018.PubMed/NCBI View Article : Google Scholar
29	Menard S, Pupa SM, Campiglio M and Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene. 22:6570–6578. 2003.PubMed/NCBI View Article : Google Scholar
30	Vasudev NS and Reynolds AR: Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions. Angiogenesis. 17:471–494. 2014.PubMed/NCBI View Article : Google Scholar
31	De Vita F, Borg C, Farina G, Geva R, Carton I, Cuku H, Wei R and Muro K: Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: Subgroup analysis from RAINBOW study. Future Oncol. 15:2723–2731. 2019.PubMed/NCBI View Article : Google Scholar
32	Troiani T, Napolitano S, Della Corte CM, Martini G, Martinelli E, Morgillo F and Ciardiello F: Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. ESMO Open. 1(e000088)2016.PubMed/NCBI View Article : Google Scholar
33	Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, et al: Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18:1467–1482. 2017.PubMed/NCBI View Article : Google Scholar
34	Shen X, Zhao Y, Chen X, Sun H, Liu M, Zhang W, Jiang F and Li P: Associations of PIK3CA mutations with clinical features and prognosis in gastric cancer. Future Oncol. 15:1873–1894. 2019.PubMed/NCBI View Article : Google Scholar
35	Xu DZ, Geng QR, Tian Y, Cai MY, Fang XJ, Zhan YQ, Zhou ZW, Li W, Chen YB, Sun XW, et al: Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. BMC Cancer. 10(536)2010.PubMed/NCBI View Article : Google Scholar
36	Schoop I, Maleki S, Behrens H, Krüger S, Haag J and Röcken C: p53 immunostaining cannot be used to predict TP53 mutations in gastric cancer: Results from a large Central European cohort. Hum Pathol. 105:53–66. 2020.PubMed/NCBI View Article : Google Scholar
37	Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014.PubMed/NCBI View Article : Google Scholar
38	Tannock I and Hickman J: Limits to personalized cancer medicine. N Engl J Med. 375:1289–1294. 2016.PubMed/NCBI View Article : Google Scholar
39	Goussia AC, Papoudou-Bai A, Charchanti A, Kitsoulis P, Kanavaros P, Kalef-Ezra J, Stefanou D and Agnantis NJ: Alterations of p53 and Rb pathways are associated with high proliferation in bladder urothelial carcinomas. Anticancer Res. 38:3985–3988. 2018.PubMed/NCBI View Article : Google Scholar
40	Ma Z, Yang Y, Di S, Feng X, Liu D, Jiang S, Hu W, Qin Z, Li Y, Lv J, et al: Pterostilbene exerts anticancer activity on non-small-cell lung cancer via activating endoplasmic reticulum stress. Sci Rep. 7(8091)2017.PubMed/NCBI View Article : Google Scholar
41	Navarro-Yepes J, Burns M, Anandhan A, Khalimonchuk O, del Razo LM, Quintanilla-Vega B, Pappa A, Panayiotidis MI and Franco R: Oxidative stress, redox signaling, and autophagy: Cell death versus survival. Antioxid Redox Signal. 21:66–85. 2014.PubMed/NCBI View Article : Google Scholar
42	Yaprak E, Kasap M, Akpinar G, Kayaalti-Y üksek S, Sinanoğlu A, Guzel N and Demirturk Kocasarac H: The prominent proteins expressed in healthy gingiva: A pilot exploratory tissue proteomics study. Odontology. 106:19–28. 2018.PubMed/NCBI View Article : Google Scholar
43	Kung CP, Khaku S, Jennis M, Zhou Y and Murphy ME: Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes. Mol Cancer Res. 13:250–262. 2015.PubMed/NCBI View Article : Google Scholar
44	van Ginkel PR, Yan MB, Bhattacharya S, Polans AS and Kenealey JD: Natural products induce a G protein-mediated calcium pathway activating p53 in cancer cells. Toxicol Appl Pharmacol. 288:453–462. 2015.PubMed/NCBI View Article : Google Scholar
45	Lin CC, Lee IT, Wu WL, Lin WN and Yang CM: Adenosine triphosphate regulates NADPH oxidase activity leading to hydrogen peroxide production and COX-2/PGE2 expression in A549 cells. Am J Physiol Lung Cell Mol Physiol. 303:L401–L412. 2012.PubMed/NCBI View Article : Google Scholar
46	Chiarugi P: From anchorage dependent proliferation to survival: Lessons from redox signalling. IUBMB Life. 60:301–307. 2008.PubMed/NCBI View Article : Google Scholar
47	Au S, Storey B, Moore J, Tang Q, Chen Y, Javaid S, Sarioglu A, Sullivan R, Madden M, O'Keefe R, et al: Clusters of circulating tumor cells traverse capillary-sized vessels. Proc Natl Acad Sci USA. 113:4947–4952. 2016.PubMed/NCBI View Article : Google Scholar
48	Vlahakis A and Debnath J: The Interconnections between autophagy and integrin-mediated cell adhesion. J Mol Biol. 429:515–530. 2017.PubMed/NCBI View Article : Google Scholar
49	Xiao T, Xu Z, Zhou Y, Zhang H, Geng J, Liang Y, Qiao H and Suo G: Loss of TP53I11 enhances the extracellular Matrix-independent survival by promoting activation of AMPK. IUBMB Life. 71:183–191. 2019.PubMed/NCBI View Article : Google Scholar
50	Otterbein LR, Graceffa P and Dominguez R: The crystal structure of uncomplexed actin in the ADP state. Science. 293:708–711. 2001.PubMed/NCBI View Article : Google Scholar
51	Harrison JD and Fielding JW: Prognostic factors for gastric cancer influencing clinical practice. World J Surg. 19:496–500. 1995.PubMed/NCBI View Article : Google Scholar